Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CEMIP1 and TACSTD2 as circulating mRNA biomarkers for early detection and tumor burden assessment in colorectal neoplasia. | Mol Med | 2026 | 42350952 | PubTator, text mining | PubMed |
| TROP2-directed antibody-drug conjugates: new first-line treatment for all patients with advanced triple-negative breast cancer? | Ann Oncol | 2026 | 42349785 | PubTator, text mining | PubMed |
| Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer. | Future Oncol | 2026 | 42345080 | PubTator, text mining | PubMed |
Comprehensive analysis of antibody-drug conjugate (ADC) targets in adenoid cystic carcinoma: examining antigen expression in relation to clinicopathological features, prognosis, and initial therapeutic outcomes. | Transl Oncol | 2026 | 42341371 | PubTator, text mining | PubMed |
| Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates. | Cancer Treat Rev | 2026 | 42341369 | PubTator, text mining | PubMed |
| Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC). | ESMO Open | 2026 | 42330841 | PubTator, text mining | PubMed |
| Trophoblast cell-surface antigen 2 evaluation in intraepithelial neoplasia and intraductal carcinoma of the prostate: An immunopathological study. | Tissue Cell | 2026 | 42330802 | PubTator, text mining | PubMed |
| SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. | Ann Oncol | 2026 | 42323161 | PubTator, text mining | PubMed |
| Structural choreography of bacteriophage N4 ejection proteins and the giant virion-associated RNA polymerase. | Nat Commun | 2026 | 42315514 | PubTator, text mining | PubMed |
| Targeting drug-tolerant persister cells: Let's bring on the TROPs! | Cancer Cell | 2026 | 42314666 | PubTator, text mining | PubMed |
| Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. | Cancer Cell | 2026 | 42314664 | PubTator, text mining | PubMed |
| Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells. | Proc Natl Acad Sci U S A | 2026 | 42308036 | PubTator, text mining | PubMed |
| A Cathepsin B-Cleavable Self-Immolative Linker for the Delivery of Hydroxyl-Containing Payloads in Antibody-Drug Conjugates. | Bioconjug Chem | 2026 | 42307382 | PubTator, text mining | PubMed |
| Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy. | NPJ Precis Oncol | 2026 | 42297906 | PubTator, text mining | PubMed |
| Trop-2 expression is associated with poor survival in pleural mesothelioma. | Front Oncol | 2026 | 42294312 | PubTator, text mining | PubMed |
| Clinicopathological and molecular characterization of HPV-associated cervical poorly cohesive carcinoma: a rare aggressive entity. | J Pathol Clin Res | 2026 | 42289532 | PubTator, text mining | PubMed |
| Redefining the Treatment Landscape of Advanced Endometrial Cancer in the Era of Immunotherapy and Precision Oncology. | Cancers (Basel) | 2026 | 42279419 | PubTator, text mining | PubMed |
| TROP2 as a promising therapeutic target in lung cancer: Current clinical trial landscape and future directions. | Pulm Pharmacol Ther | 2026 | 42263842 | PubTator, text mining | PubMed |
| Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors. | JCO Precis Oncol | 2026 | 42258781 | PubTator, text mining | PubMed |
| Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset. | Int J Urol | 2026 | 42252959 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=7